Despite the threat of a looming climate catastrophe, low oil prices and giant industrial conglomerates addicted to fossil resources continue to stifle industrial biotechnology products and innovation. The European Biotechnology Network is now providing a foot up for companies that want to help themselves by launching three very different projects aimed at pushing the bioeconomy forward.
Mutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund.
Critical care experts have presented data supporting the thesis that three specific pathways are the cause for about 90% of sepsis mortality.
Norwegian biopharma company Zelluna Immunotherapy appointed erstwhile CSO Namir Hassan as Chief Executive Officer.
Antabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients
Creoptix AG, a Switzerland-based company focused on next-generation bioanalytical instruments, has named Line Stigen Raquet as Chief Executive Officer.
Swedish and Danish researchers have created a hydrogel that kills various types of bacteria and reduces inflammation in mice and pigs with infected wounds.